89bio Past Earnings Performance

Past criteria checks 0/6

89bio's earnings have been declining at an average annual rate of -30.7%, while the Biotechs industry saw earnings growing at 19.1% annually.

Key information

-30.7%

Earnings growth rate

66.0%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-76.4%
Net Margin	n/a
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How 89bio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:ETNB Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	-289	37	267
30 Jun 24	-175	34	157
31 Mar 24	-165	33	147
31 Dec 23	-142	29	122
30 Sep 23	-127	28	108
30 Jun 23	-119	25	98
31 Mar 23	-105	22	83
31 Dec 22	-102	21	81
30 Sep 22	-104	20	83
30 Jun 22	-105	20	84
31 Mar 22	-101	20	80
31 Dec 21	-90	19	70
30 Sep 21	-76	18	58
30 Jun 21	-63	17	46
31 Mar 21	-54	15	39
31 Dec 20	-49	13	36
30 Sep 20	-56	12	35
30 Jun 20	-60	10	30
31 Mar 20	-64	8	25
31 Dec 19	-57	5	21
30 Sep 19	-44	4	19
30 Jun 19	-30	3	16

Quality Earnings: ETNB is currently unprofitable.

Growing Profit Margin: ETNB is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ETNB is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.

Accelerating Growth: Unable to compare ETNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ETNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: ETNB has a negative Return on Equity (-76.42%), as it is currently unprofitable.

89bio Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $124.996747 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval

COO & Chief Business Officer exercised options and sold US$104k worth of stock

CEO & Director recently bought US$118k worth of stock

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

COO & Chief Business Officer exercised options and sold US$124k worth of stock

89Bio Initiates Phase 2B Enliven Trial of Bio89-100 for the Treatment of Nash

COO & Chief Business Officer notifies of intention to sell stock

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio, Inc. Announces Additional Positive Data from its Phase 1b/2a Study of BIO89-100 to Be Present at the Annual Endo 2021 Conference

COO & Chief Business Officer exercised options and sold US$156k worth of stock

Independent Director exercised options to buy US$2.0m worth of stock.

89bio: NASH Drug Developer With Differentiated Profile